APTO - Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

• A lack of progress in the clinic, including another disappointing ASH meeting, has led investors to bail out of this risky early-stage biotech.
• A new formulation of luxeptinib, and potentially greater exposure to the drug, may finally unlock the potential of this once-promising drug, but it's a "show me" story.
• Recently-acquired '239 looks like an interesting asset for AML, with promising Phase 1 response rates, but it's still early in the development cycle.
• Between '239 and luxeptinib there is still potential in Aptose's pipeline, but it will take real evidence of clinical efficacy to rebuild sentiment.

For further details see: